Back to results
US 2026/0085070 A1Published application
Heterocyclic cbl-b inhibitors for the treatment of cancer
AssigneeHotspot Therapeutics, Inc.
InventorsYingzhi BI, Kenneth G. CARSON, Geraldine Cirillo HARRIMAN
Life of this patent
Estimating the term…
Abstract
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
Claims22
A compound of formula (A):
- or pharmaceutically acceptable salts thereof,
- wherein
- X is optionally substituted phenyl or optionally substituted 5-6 membered heteroaryl;
- Y is —N═ or —C(H)═;
- R* is selected from the group consisting of —CH2-A, —CH2—O-A, —CH2—O—CH2-A, —CH2N(H)-A, —CH(CH3)N(H)-A, and —CH2N(H)CH2-A;
- Rb is selected from the group consisting of hydrogen, halogen, —OR1, and optionally substituted C1-C3 alkyl;
- Rc is optionally substituted C1-C3 alkyl;
- Rd is selected from the group consisting of hydrogen, halogen, optionally substituted C3-C7 carbocylyl, —OR1, and —NR1R2;
- Re is hydrogen or halogen;
- A is selected from the group consisting of —OH, —OR1, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C7 carbocylyl, and optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, wherein A is optionally substituted with 1-5 instances of Ra1;
- each Ra1 is independently selected from the group consisting of halogen, —CN, —OH, —OR1, —NH2, —NR1R2, —SH, —SR1, —SF5, —CO2H, —CO2R1, —CONH2, —CONR1R2, —SO2NH2, —SO2NR1R2, —SO2OH, —SO2OR1, —S(O)R1, —S(O)2R1, —S(O)(NH)R1, —S(O)(NR1)R1, optionally substituted C1-C6 aliphatic, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S,
- wherein two instances of Ra1 are optionally taken together to form an optionally substituted C3-C7 carbocylyl or optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S;
- each R1 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, —C(O)R3, —CO2R3, —C(O)NHR3, and —SO2R3;
- each R2 is independently selected from the group consisting of hydrogen, optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
- or R1 and R2 are taken together with their intervening atom(s) to form a 3-8-membered heterocyclyl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S, or an optionally substituted 5-6-membered heteroaryl ring containing 1-4 heteroatoms selected from the group consisting of N, O, and S;
- and
- each R3 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S.
14 more elements
A compound selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
22-33. (canceled)
Dependencies are inferred from the claim text.